U.S. merger and acquisition deal volume rebounded in the first quarter, climbing to its highest level since 2022 despite aggressive antitrust scrutiny from federal agencies.
Technology and health care sectors led the recovery, with several multibillion-dollar strategic transactions announced.
Practitioners report longer regulatory timelines but growing certainty around the agencies' analytical frameworks.
